Uric acid as a danger signal in gout and its comorbidities

Nature Reviews Rheumatology

Volumn 9, Issue 1, 2013, Pages 13-23

  Rock, Kenneth L ^a   Kataoka, Hiroshi ^a   Lai, Jiann Jyh ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; AMYLOID BETA PROTEIN; ASBESTOS; CALCIUM PHOSPHATE; CALCIUM PYROPHOSPHATE; CANAKINUMAB; COLCHICINE; CRYOPYRIN; CXCL1 CHEMOKINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SILICON DIOXIDE; TITANIUM; TOLL LIKE RECEPTOR; URATE; URIC ACID; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR;

ADAPTIVE IMMUNITY; CARDIOVASCULAR DISEASE; CELL DAMAGE; COMORBIDITY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; IMMUNE RESPONSE; INFECTION; INFLAMMATION; INNATE IMMUNITY; KIDNEY DISEASE; METABOLIC SYNDROME X; MOLECULAR PATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PURINE METABOLISM; RESPIRATORY TRACT DISEASE; REVIEW; URIC ACID BLOOD LEVEL;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COMORBIDITY; CRYSTALLIZATION; DIABETES MELLITUS; GOUT; HUMANS; HYPERTENSION; INFLAMMATION; INTERLEUKIN-1; URIC ACID;

EID: 84871733357     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.143     Document Type: Review

References (131)

1. Zhu, Y., Pandya, B. J. & Choi, H. K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 63, 3136-3141 (2011).
2. Richette, P. & Bardin, T. Gout. Lancet 375, 318-328 (2010).
3. Pillinger, M. H., Goldfarb, D. S. & Keenan, R. T. Gout and its comorbidities. Bull. NYU Hosp. Jt Dis. 68, 199-203 (2010).
4. Shi, Y., Evans, J. E. & Rock, K. L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425, 516-521 (2003). (Pubitemid 37237047)
5. So, A. & Thorens, B. Uric acid transport and disease. J. Clin. Invest. 120, 1791-1799 (2010).
6. Ames, B. N., Cathcart, R., Schwiers, E. & Hochstein, P. Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc. Natl Acad. Sci. USA 78, 6858-6862 (1981). (Pubitemid 12216861)
7. Frayha, R. A., Salti, I. S., Arnaout, A., Khatchadurian, A. & Uthman, S. M. Hereditary xanthinuria: report on three patients and short review of the literature. Nephron 19, 328-332 (1977). (Pubitemid 8196094)
8. Liu, B. et al. Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. Neurol. Res. 34, 163-171 (2012).
9. Schwarzschild, M. A. et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch. Neurol. 65, 716-723 (2008). (Pubitemid 351831449)
10. Alvarez-Lario, B. & Macarron-Vicente, J. Uric acid and evolution. Rheumatology (Oxford) 49, 2010-2015 (2010).
11. Kutzing, M. K. & Firestein, B. L. Altered uric acid levels and disease states. J. Pharmacol. Exp. Ther. 324, 1-7 (2008). (Pubitemid 350294141)
12. Kumar, H., Kawai, T. & Akira, S. Pathogen recognition by the innate immune system. Int. Rev. Immunol. 30, 16-34 (2011).
13. Matzinger, P. The danger model: a renewed sense of self. Science 296, 301-305 (2002). (Pubitemid 34303674)
14. Rock, K. L. & Kono, H. The inflammatory response to cell death. Annu. Rev. Pathol. 3, 99-126 (2008). (Pubitemid 351488277)
15. Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998). (Pubitemid 28155090)
16. Greenfield, E. A., Nguyen, K. A. & Kuchroo, V. K. CD28/B7 costimulation: a review. Crit. Rev. Immunol. 18, 389-418 (1998). (Pubitemid 28447017)
17. Rock, K. L., Hearn, A., Chen, C. J. & Shi, Y. Natural endogenous adjuvants. Springer Semin. Immunopathol. 26, 231-246 (2005).
18. Albert, M. L., Sauter, B. & Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86-89 (1998). (Pubitemid 28150594)
19. Rovere, P. et al. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J. Immunol. 161, 4467-4471 (1998). (Pubitemid 28492012)
20. Gallucci, S., Lolkema, M. & Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5, 1249-1255 (1999). (Pubitemid 29535601)
21. Shi, Y., Zheng, W. & Rock, K. L. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc. Natl Acad. Sci. USA 97, 14590-14595 (2000). (Pubitemid 32016620)
22. Kono, H., Chen, C. J., Ontiveros, F. & Rock, K. L. Uric acid promotes an acute inflammatory response to sterile cell death in mice. J. Clin. Invest. 120, 1939-1949 (2010).
23. Kono, H. & Rock, K. L. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 8, 279-289 (2008). (Pubitemid 351432799)
24. Deapen, D. et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 35, 311-318 (1992).
25. Shi, Y., Galusha, S. A. & Rock, K. L. Cutting edge: elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model. J. Immunol. 176, 3905-3908 (2006). (Pubitemid 44264366)
26. Allam, R. & Anders, H. J. The role of innate immunity in autoimmune tissue injury. Curr. Opin. Rheumatol. 20, 538-544 (2008).
27. Like, A. A. & Rossini, A. A. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 193, 415-417 (1976).
28. Horwitz, M. S., Ilic, A., Fine, C, Rodriguez, E. & Sarvetnick, N. Presented antigen from damaged pancreatic ß cells activates autoreactive T cells in virus-mediated autoimmune diabetes. J. Clin. Invest. 109, 79-87 (2002). (Pubitemid 34052544)
29. Kurts, C, Miller, J. F., Subramaniam, R. M., Carbone, F. R. & Heath, W. R. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J. Exp. Med. 188, 409-414 (1998). (Pubitemid 28357770)
30. Horwitz, M. S. et al. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med. 4, 781-785 (1998). (Pubitemid 28331018)
31. nd edn (Oxford University Press, New York, 2004).
32. Kono, H., Karmarkar, D., Iwakura, Y. & Rock, K. L. Identification of the cellular sensor that stimulates the inflammatory response to sterile cell death. J. Immunol. 184, 4470-4478 (2010).
33. Rock, K. L, Latz, E., Ontiveros, F. & Kono, H. The sterile inflammatory response. Annu. Rev. Immunol. 28, 321-342 (2010).
34. Mertens, M. & Singh, J. A. Anakinra for rheumatoid arthritis: a systematic review. J. Rheumatol. 36, 1118-1125 (2009).
35. Rock, K. L, Lai, J. J. & Kono, H. Innate and adaptive immune responses to cell death. Immunol. Rev. 243, 191-205 (2011).
36. Chen, C. J. et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J. Clin. Invest. 116, 2262-2271 (2006).
37. Gasse, P. et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am. J. Respir. Crit. Care Med. 179, 903-913 (2009).
38. Dinarello, C. A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117, 3720-3732 (2011).
39. Eigenbrod, T., Park, J. H., Harder, J., Iwakura, Y & Nunez, G. Cutting edge: critical role for mesothelial cells in necrosis-induced inflammation through the recognition of IL-1a released from dying cells. J. Immunol. 181, 8194-8198 (2008).
40. Gross, O. et al. Inflammasome activators induce interleukin-1a secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 36, 388-400 (2012).
41. Dinarello, C. A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27, 519-550 (2009).
42. Bauernfeind, F G. et al. Cutting edge: NF-KB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183, 787-791 (2009).
43. Martinon, F, Burns, K. & Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-ß. Mol. Cell 10, 417-426 (2002). (Pubitemid 35007355)
44. Schroder, K. & Tschopp, J. The inflammasomes. Cell 140, 821-832 (2010).
45. Hoffman, H. M., Mueller, J. L, Broide, D. H., Wanderer, A. A. & Kolodner, R. D. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 29, 301-305 (2001). (Pubitemid 33096455)
46. Aksentijevich, I. et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 46, 3340-3348 (2002). (Pubitemid 35453546)
47. Kubota, T. & Koike, R. Cryopyrin-associated periodic syndromes: background and therapeutics. Mod. Rheumatol. 20, 213-221 (2010).
48. Church, L. D., Churchman, S. M., Hawkins, P. N. & McDermott, M. F. Hereditary auto-inflammatory disorders and biologics. Springer Semin. Immunopathol. 27, 494-508 (2006).
49. Kobayashi, Y. et al. Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1α. Proc. Natl Acad. Sci. USA 87, 5548-5552 (1990).
50. Afonina, I. S. et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1α. Mol. Cell 44, 265-278 (2011).
51. Fettelschoss, A. et al. Inflammasome activation and IL-1β target IL-1α for secretion as opposed to surface expression. Proc. Natl Acad. Sci. USA 108, 18055-18060 (2011).
52. Kuida, K. et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1β converting enzyme. Science 267, 2000-2003 (1995).
53. Sutterwala, F. S. et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24, 317-327 (2006).
54. Hornung, V. et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9, 847-856 (2008).
55. Latz, E. The inflammasomes: mechanisms of activation and function. Curr. Opin. Immunol. 22, 28-33 (2010).
56. Nuki, G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr. Rheumatol. Rep. 10, 218-227 (2008).
57. McCarty, D. J. Urate crystals, inflammation, and colchicine. Arthritis Rheum. 58 (Suppl. S2), S20-S24 (2008). (Pubitemid 351281120)
58. Eisenbarth, S. C., Colegio, O. R., O'Connor, W., Sutterwala, F. S. & Flavell, R. A. Crucial role for the NALP3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453, 1122-1126 (2008). (Pubitemid 351871731)
59. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 (2006). (Pubitemid 43372104)
60. Cronstein, B. N. et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J. Clin. Invest. 96, 994-1002 (1995).
61. Dostert, C. et al. Innate immune activation through NALP3 inflammasome sensing of asbestos and silica. Science 320, 674-677 (2008). (Pubitemid 351928351)
62. Zhou, R., Tardivel, A., Thorens, B., Choi, I. & Tschopp, J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11, 136-140 (2010).
63. Bauernfeind, F. et al. Inflammasomes: current understanding and open questions. Cell. Mol. Life Sci. 68, 765-783 (2011).
64. Zhou, R., Yazdi, A. S., Menu, P. & Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221-225 (2011).
65. Masters, S. L. et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat. Immunol. 11, 897-904 (2010).
66. Halle, A. et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat. Immunol. 9, 857-865 (2008).
67. Hentze, H., Lin, X. Y., Choi, M. S. & Porter, A. G. Critical role for cathepsin B in mediating caspase-1-dependent interleukin-18 maturation and caspase-1-independent necrosis triggered by the microbial toxin nigericin. Cell Death Differ. 10, 956-968 (2003). (Pubitemid 37069473)
68. Sharp, F. A. et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl Acad. Sci. USA 106, 870-875 (2009).
69. Dostert, C. et al. Malarial hemozoin is a NALP3 inflammasome activating danger signal. PLoS ONE 4, e6510 (2009).
70. Gross, O. et al. Syk kinase signalling couples to the NLRP3 inflammasome for anti-fungal host defence. Nature 459, 433-436 (2009).
71. Hoffstein, S. & Weissmann, G. Mechanisms of lysosomal enzyme release from leukocytes. I V. Interaction of monosodium urate crystals with dogfish and human leukocytes. Arthritis Rheum. 18, 153-165 (1975).
72. Petrilli, V. et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 14, 1583-1589 (2007). (Pubitemid 47278844)
73. Chen, G. Y. & Nunez, G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 10, 826-837 (2010).
74. Leemans, J. C., Cassel, S. L. & Sutterwala, F. S. Sensing damage by the NLRP3 inflammasome. Immunol. Rev. 243, 152-162 (2011).
75. Shimada, K. et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36, 401-414 (2012).
76. Joosten, L. A. et al. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1β. Arthritis Rheum. 60, 3651-3662 (2009).
77. Guma, M. et al. Caspase 1-independent activation of interleukin-1β in neutrophil-predominant inflammation. Arthritis Rheum. 60, 3642-3650 (2009).
78. Hazuda, D. J., Strickler, J., Kueppers, F., Simon, P. L. & Young, P. R. Processing of precursor interleukin 1β and inflammatory disease. J. Biol. Chem. 265, 6318-6322 (1990).
79. Mizutani, H., Schechter, N., Lazarus, G., Black, R. A. & Kupper, T. S. Rapid and specific conversion of precursor interleukin 1β (IL-1β) to an active IL-1 species by human mast cell chymase. J. Exp. Med. 174, 821-825 (1991).
80. Schonbeck, U., Mach, F. & Libby, P. Generation of biologically active IL-1β by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1β processing. J. Immunol. 161, 3340-3346 (1998).
81. Coeshott, C. et al. Converting enzyme-independent release of tumor necrosis factor α and IL-1β from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc. Natl Acad. Sci. USA 96, 6261-6266 (1999). (Pubitemid 29256653)
82. Pham, C. T. & Ley, T. J. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc. Natl Acad. Sci. USA 96, 8627-8632 (1999). (Pubitemid 29354842)
83. McGuire, M. J., Lipsky, P. E. & Thiele, D. L. Generation of active myeloid and lymphoid granule serine proteases requires processing by the granule thiol protease dipeptidyl peptidase I. J. Biol. Chem. 268, 2458-2467 (1993). (Pubitemid 23057866)
84. Adkison, A. M., Raptis, S. Z., Kelley, D. G. & Pham, C. T. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J. Clin. Invest. 109, 363-371 (2002). (Pubitemid 34141810)
85. Liu-Bryan, R., Pritzker, K., Firestein, G. S. & Terkeltaub, R. TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J. Immunol. 174, 5016-5023 (2005). (Pubitemid 40514462)
86. Joosten, L. A. et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum. 62, 3237-3248 (2010).
87. Ng, G. et al. Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. Immunity 29, 807-818 (2008).
88. Scott, P., Ma, H., Viriyakosol, S., Terkeltaub, R. & Liu-Bryan, R. Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals. J. Immunol. 177, 6370-6378 (2006). (Pubitemid 44642121)
89. Popa-Nita, O., Proulx, S., Pare, G., Rollet-Labelle, E. & Naccache, P. H. Crystal-induced neutrophil activation: XI. Implication and novel roles of classical protein kinase C. J. Immunol. 183, 2104-2114 (2009).
90. Tramontini, N., Huber, C., Liu-Bryan, R., Terkeltaub, R. A. & Kilgore, K. S. Central role of complement membrane attack complex in monosodium urate crystal-induced neutrophilic rabbit knee synovitis. Arthritis Rheum. 50, 2633-2639 (2004). (Pubitemid 39062725)
91. Pouliot, M., James, M. J., McColl, S. R., Naccache, P. H. & Cleland, L. G. Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes. Blood 91, 1769-1776 (1998). (Pubitemid 28110344)
92. Kuroda, E. et al. Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity 34, 514-526 (2011).
93. Krishnan, E. Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Rheumatology (Oxford) 49, 1229-1238 (2010).
94. Ichikawa, N., Taniguchi, A., Urano, W., Nakajima, A. & Yamanaka, H. Comorbidities in patients with gout. Nucleosides Nucleotides Nucleic Acids 30, 1045-1050 (2011).
95. Khosla, U. M. et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 67, 1739-1742 (2005). (Pubitemid 40577708)
96. Mazzali, M. et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38, 1101-1106 (2001). (Pubitemid 34252813)
97. Mazzali, M. et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am. J. Physiol. Renal Physiol. 282, F991-F997 (2002). (Pubitemid 34654464)
98. Farquharson, C. A., Butler, R., Hill, A., Belch, J. J. & Struthers, A. D. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 106, 221-226 (2002). (Pubitemid 34761303)
99. 2+ exchanger-mediated mitochondrial calcium overload. Cell Calcium 51, 402-410 (2012).
100. Puddu, P., Puddu, G. M., Cravero, E., Vizioli, L. & Muscari, A. The relationships among hyperuricemia, endothelial dysfunction, and cardiovascular diseases: molecular mechanisms and clinical implications. J. Cardiol. 59, 235-242 (2012).
101. Zharikov, S. et al. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am. J. Physiol. Cell Physiol. 295, C1183-C1190 (2008). (Pubitemid 352790338)
102. Nakagawa, T. et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am. J. Physiol. Renal Physiol. 290, F625-F631 (2006). (Pubitemid 43724964)
103. Vandanmagsar, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179-188 (2011).
104. Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357-1361 (2010).
105. Dalekos, G. N., Elisaf, M., Bairaktari, E., Tsolas, O. & Siamopoulos, K. C. Increased serum levels of interleukin-1β in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients? J. Lab. Clin. Med. 129, 300-308 (1997). (Pubitemid 27169432)
106. Dalekos, G. N., Elisaf, M. S., Papagalanis, N., Tzallas, C. & Siamopoulos, K. C. Elevated interleukin-1β in the circulation of patients with essential hypertension before any drug therapy: a pilot study. Eur. J. Clin. Invest. 26, 936-939 (1996). (Pubitemid 26343786)
107. Peeters, A. C. et al. Pro-inflammatory cytokines in patients with essential hypertension. Eur. J. Clin. Invest. 31, 31-36 (2001). (Pubitemid 32151119)
108. Ruggiero, C. et al. Uric acid and inflammatory markers. Eur. Heart J. 27, 1174-1181 (2006).
109. Vekic, J. et al. High serum uric acid and low-grade inflammation are associated with smaller LDL and HDL particles. Atherosclerosis 203, 236-242 (2009).
110. Chhana, A. et al. Monosodium urate monohydrate crystals inhibit osteoblast viability and function: implications for development of bone erosion in gout. Ann. Rheum. Dis. 70, 1684-1691 (2011).
111. Schlesinger, N. & Thiele, R. G. The pathogenesis of bone erosions in gouty arthritis. Ann. Rheum. Dis. 69, 1907-1912 (2010).
112. So, A., De Smedt, T., Revaz, S. & Tschopp, J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9, R28 (2007).
113. Schumacher, H. R. Jr. et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 64, 876-884 (2012).
114. Schlesinger, N. et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann. Rheum. Dis. 70, 1264-1271 (2011).
115. Schlesinger, N. et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res. Ther. 13, R53 (2011).
116. So, A. et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 62, 3064-3076 (2010).
117. Burnet, F. M. Immunological recognition of self. Science 133, 307-311 (1961).
118. York, I. A., Goldberg, A. L., Mo, X. Y. & Rock, K. L. Proteolysis and class I major histocompatibility complex antigen presentation. Immunol. Rev. 172, 49-66 (1999). (Pubitemid 30000468)
119. Germain, R. N. & Margulies, D. H. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 11, 403-450 (1993). (Pubitemid 23115014)
120. Hoffman, H. M. et al. Role of the leucine-rich repeat domain of cryopyrin/NALP3 in monosodium urate crystal-induced inflammation in mice. Arthritis Rheum. 62, 2170-2179 (2010).
121. Torres, R. et al. Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Ann. Rheum. Dis 68, 1602-1608 (2009).
122. Cassel, S. L. et al. The NALP3 inflammasome is essential for the development of silicosis. Proc. Natl Acad. Sci. USA 105, 9035-9040 (2008).
123. Palomaki, J. et al. Long, needle-like carbon nanotubes and asbestos activate the NLRP3 inflammasome through a similar mechanism. ACS Nano 5, 6861-6870 (2011).
124. Rajamaki, K. et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS ONE 5, e11765 (2010).
125. Li, H., Willingham, S. B., Ting, J. P. & Re, F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J. Immunol. 181, 17-21 (2008).
126. Franchi, L. & Nunez, G. The NLRP3 inflammasome is critical for aluminium hydroxide-mediated IL-1β secretion but dispensable for adjuvant activity. Eur. J. Immunol. 38, 2085-2089 (2008).
127. Kool, M. et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J. Immunol. 181, 3755-3759 (2008).
128. Pazar, B. et al. Basic calcium phosphate crystals induce monocyte/macrophage IL-1β secretion through the NLRP3 inflammasome in vitro. J. Immunol. 186, 2495-2502 (2011).
129. Narayan, S. et al. Octacalcium phosphate crystals induce inflammation in vivo through interleukin-1 but independent of the NLRP3 inflammasome in mice. Arthritis Rheum. 63, 422-433 (2011).
130. Jin, C. et al. NLRP3 inflammasome plays a critical role in the pathogenesis of hydroxyapatite-associated arthropathy. Proc. Natl Acad. Sci. USA 108, 14867-14872 (2011).
131. Yazdi, A. S. et al. Nanoparticles activate the NLR pyrin domain containing 3 (NLRP3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1β. Proc. Natl Acad. Sci. USA 107, 19449-19454 (2010).